Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2

• Published in: Modern pathology Vol. 37; no. 3; p. 100424
• Main Authors: Posada, Jessica M., Yakirevich, Evgeny, Kamat, Ashish M., Sood, Akshay, Jacob, Joseph M., Bratslavsky, Gennady, Grivas, Petros, Spiess, Philippe E., Li, Roger, Necchi, Andrea, Mega, Anthony E., Golijanin, Dragan J., Pavlick, Dean, Huang, Richard S.P., Lin, Douglas, Danziger, Natalie, Sokol, Ethan S., Sivakumar, Smruthy, Ross, Jeffrey S., Cheng, Liang
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2024
• Subjects: Biomarkers, Tumor - genetics; bladder; Carcinoma, Transitional Cell - genetics; Carcinoma, Transitional Cell - pathology; ERBB2/HER2; Genomics; Humans; micropapillary subtype; molecular genetics; Mutation; Receptor, ErbB-2 - genetics; targeted therapy; Urinary Bladder - pathology; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - pathology; urothelial carcinoma; molecular genetics; targeted therapy; urothelial carcinoma; micropapillary subtype; ERBB2/HER2; bladder
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1016/j.modpat.2024.100424

The micropapillary subtype of urothelial carcinoma (MPUC) of the bladder is a very aggressive histological variant of urothelial bladder cancer (UBC). A high frequency of MPUC contains activating mutations in the extracellular domain (ECD) of ERBB2. We sought to further characterize ERBB2 ECD-mutated MPUC to identify additional genomic alterations that have been associated with tumor progression and therapeutic response. In total, 5,485 cases of archived formalin-fixed, paraffin-embedded UBC underwent comprehensive genomic profiling to identify ERBB2 ECD-mutated MPUC and evaluate the frequencies of genomic co-alterations. We identified 219 cases of UBC with ERBB2 ECD mutations (74% S310F and 26% S310Y), of which 63 (28.8%) were MPUC. Genomic analysis revealed that TERT, TP53, and ARID1A were the most common co-altered genes in ERBB2-mutant MPUC (82.5%, 58.7%, and 39.7%, respectively) and did not differ from ERBB2-mutant non-MPUC (86.5%, 51.9%, and 35.3%). The main differences between ERBB2 ECD-mutated MPUC compared with non-MPUC were KMT2D, RB1, and MTAP alterations. KMT2D and RB1 are tumor-suppressor genes. KMT2D frequency was significantly decreased in ERBB2 ECD-mutated MPUC (6.3%) in contrast to non-MPUC (27.6%; P < .001). RB1 mutations were more frequent in ERBB2 ECD-mutated MPUC (33.3%) than in non-MPUC (17.3%; P = .012). Finally, MTAP loss, an emerging biomarker for new synthetic lethality-based anticancer drugs, was less frequent in ERBB2 ECD-mutated MPUC (11.1%) than in non-MPUC (26.9%; P = .018). Characterizing the genomic landscape of MPUC may not only improve our fundamental knowledge about this aggressive morphological variant of UBC but also has the potential to identify possible prognostic and predictive biomarkers that may drive tumor progression and dictate treatment response to therapeutic approaches.